Lehne's Pharmacotherapeutics for Advanced Practice Nurses and Physician Assistants
- 3rd Edition - October 16, 2024
- Imprint: Elsevier
- Authors: Laura D. Rosenthal, Jacqueline Rosenjack Burchum
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 3 6 0 6 - 4
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 3 6 7 9 - 8
**Selected for 2025 Doody’s Core Titles® with "Essential Purchase" designation in Advanced Practice**Lehne's Pharmacotherapeutics for Advanced Practice Nurses and Physician… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quote**Selected for 2025 Doody’s Core Titles® with "Essential Purchase" designation in Advanced Practice**
Lehne's Pharmacotherapeutics for Advanced Practice Nurses and Physician Assistants, Third Edition builds on the same foundation of clearly explained, up-to-date, and clinically current content as Lehne’s trusted undergraduate text, while focusing on the information that advanced practice nurses and Physician Assistants specifically need for safe and effective prescribing. Introductory chapters provide foundational content in the areas of prescriptive authority, rational drug selection, prescription writing, and promoting positive outcomes of drug therapy. Core drug chapters focus on the drugs that you will most commonly see in clinical practice. Pharmacotherapeutic decision-making is emphasized, with Black Box Warnings and new Drug Decision Guide boxes. This edition features completely updated content with new chapters on drugs for sexual dysfunction and drugs for transgender health. It’s everything you need to be a safe and effective prescriber!
Lehne's Pharmacotherapeutics for Advanced Practice Nurses and Physician Assistants, Third Edition builds on the same foundation of clearly explained, up-to-date, and clinically current content as Lehne’s trusted undergraduate text, while focusing on the information that advanced practice nurses and Physician Assistants specifically need for safe and effective prescribing. Introductory chapters provide foundational content in the areas of prescriptive authority, rational drug selection, prescription writing, and promoting positive outcomes of drug therapy. Core drug chapters focus on the drugs that you will most commonly see in clinical practice. Pharmacotherapeutic decision-making is emphasized, with Black Box Warnings and new Drug Decision Guide boxes. This edition features completely updated content with new chapters on drugs for sexual dysfunction and drugs for transgender health. It’s everything you need to be a safe and effective prescriber!
- UPDATED! Content throughout reflects the latest drug information and evidence-based treatment guidelines and protocols
- NEW! Drugs for Sexual Dysfunction and Drugs for Transgender Health chapters in a newly combined Reproductive Health unit promote health equity
- NEW! Drug Decision Guide boxes for selected drugs emphasize a rational process for drug selection
- NEW! Clinical Pearls boxes highlight expert tips for rational drug prescription
- NEW! Chapter-opening Evolve links and “Top 300” drug icons throughout identify drugs that appear on the Top 300 prescribed drug list to help you focus your study time
- ENHANCED! Introductory chapters emphasize prescriber-level pharmacokinetics and pharmacodynamics content
- NEW! Coverage addresses immunizations and therapeutics (e.g., Regeneron, Resdemivir, dexamethasone) for SARS-CoV-2 infection (COVID-19)
- UPDATED! Enhanced coverage of sexually transmitted infections reflects the latest evidence-based guidelines
- NEW! Drug content addresses medications for ectoparasite infestations
- Introductory chapters tailored to the specific needs of beginning prescribers cover topics such as prescriptive authority, rational drug selection and prescription writing, and promoting positive outcomes of drug therapy
- Carefully focused pharmacotherapeutics content reflects the drugs most commonly seen and used by primary and acute care prescribers, with an emphasis not on the first drug discovered or developed in each drug class, but on the agents most often used today
- Chapters address primary care drugs first, as appropriate, followed by acute care drugs
- Prescriber-focused pedagogical aids further reinforce the most important information for prescribers
- UNIQUE! Summary of Key Prescribing Considerations at the end of each drug chapter provides a concise summary of essential prescriber information
- Coverage of interprofessional collaboration addresses the growing global emphasis on interprofessional collaboration and incorporates opportunities for interprofessional collaborative practice throughout
- Integrated coverage of Canadian trade names appears throughout and is highlighted with a familiar maple-leaf icon
Nurse Practitioner (NP) students, including those in Doctor of Nursing Practice (DNP) programs; other Advanced Practice Registered Nursing (APRN) students; Physician Assistant (PA) students
- Lehne’s Pharmacotherapeutics for Advanced Practice Nurses and Physician Assistants
- Cover image
- Title page
- Disclaimer
- Table of Contents
- Contents
- Copyright
- Dedication
- Acknowledgments
- About the authors
- Contributor and reviewers
- Preface
- List of Illustrations
- List of Tables
- UNIT I. Introduction
- 1. Prescriptive authority
- What is prescriptive authority?
- Prescriptive authority regulations
- The case for full prescriptive authority
- Prescriptive authority and responsibility
- 2. Rational drug selection and prescription writing
- Responsibility of prescribing
- Drug selection
- Prescriptions
- Assistance
- 3. Promoting positive outcomes of drug therapy
- Medication education
- Monitoring
- Adherence
- Managing medication therapy
- Summary
- UNIT II. Basic Principles of Pharmacology
- 4. Pharmacokinetics, pharmacodynamics, and drug interactions
- Pharmacokinetics
- Passage of drugs across membranes
- Polar molecules and ions
- Absorption
- Distribution
- Metabolism
- Excretion
- Time course of drug responses
- Pharmacodynamics
- Dose–response relationships
- Drug–receptor interactions
- Drug responses that do not involve receptors
- Interpatient variability in drug responses
- Therapeutic index
- Drug interactions
- Drug–drug interactions
- Drug–food interactions
- Drug–supplement interactions
- 5. Adverse drug reactions and medication errors
- Adverse drug reactions
- Medication errors
- 6. Individual variation in drug responses
- Body weight and composition
- Age
- Pathophysiology
- Tolerance
- Placebo effect
- Variability in absorption
- Genetics and pharmacogenomics
- Comorbidities
- Social determinants of health
- 7. Genetic and genomic considerations in pharmacotherapeutics
- Pharmacogenomics
- Application of pharmacogenomics
- Barriers to pharmacogenomic application in practice
- Implications and ethics
- Guidelines
- UNIT III. Drug Therapy Across the Life Span
- 8. Drug therapy during pregnancy and breastfeeding
- Drug therapy during pregnancy: Basic considerations
- Drug therapy during pregnancy: Teratogenesis and other risks
- Drug therapy during breastfeeding
- 9. Drug therapy in pediatric patients
- Pharmacokinetics: Neonates and infants
- Pharmacokinetics: Children 1 year and older
- Adverse drug reactions
- Dosage determination
- Promoting adherence
- 10. Drug therapy in geriatric patients
- Pharmacokinetic changes in older adults
- Pharmacodynamic changes in older adults
- Adverse drug reactions and drug interactions
- Promoting adherence
- Considerations for end-of-life care
- UNIT IV. Peripheral Nervous System Drugs
- 11. Basic principles of neuropharmacology
- How neurons regulate physiologic processes
- Basic mechanisms by which neuropharmacologic agents act
- Multiple receptor types and selectivity of drug action
- An approach to learning about peripheral nervous system drugs
- 12. Physiology of the peripheral nervous system
- Divisions of the nervous system
- Overview of autonomic nervous system functions
- Autonomic nervous system regulation of physiologic processes
- Anatomic considerations
- Transmitters of the peripheral nervous system
- Receptors of the peripheral nervous system
- Exploring the concept of receptor subtypes
- Locations of receptor subtypes
- Functions of cholinergic and adrenergic receptor subtypes
- Receptor specificity of the adrenergic transmitters
- Transmitter life cycles
- 13. Muscarinic agonists and cholinesterase inhibitors
- Introduction to cholinergic drugs
- Muscarinic agonists
- Cholinesterase inhibitors
- 14. Muscarinic antagonists
- Introduction to anticholinergic drugs
- Muscarinic antagonists (anticholinergic drugs)
- 15. Adrenergic agonists
- Mechanisms of adrenergic receptor activation
- Overview of the adrenergic agonists
- Therapeutic applications and adverse effects of adrenergic receptor activation
- Properties of representative adrenergic agonists
- 16. Adrenergic antagonists
- α-adrenergic antagonists
- β-adrenergic antagonists
- 17. Indirect-acting antiadrenergic agents
- Centrally acting α2 agonists
- UNIT V. Central Nervous System Drugs
- 18. Introduction to central nervous system pharmacology
- The blood-brain barrier
- Neurotransmitters of the central nervous system
- Production of therapeutic effects
- Adaptation of the central nervous system to prolonged drug exposure
- Development of new psychotherapeutic drugs
- Approaching the study of central nervous system drugs
- 19. Drugs for parkinson disease
- Pathogenesis of parkinson disease
- The pathophysiology underlying motor symptoms
- Overview of motor symptom management
- Pharmacology of the drugs used for motor symptoms
- Nonmotor symptoms and their management
- 20. Drugs for Alzheimer disease
- Pathophysiology of Alzheimer disease
- Risk factors and symptoms
- Drugs for cognitive impairment
- 21. Drugs for seizure disorders
- Generation of seizures
- Types of seizures
- How antiseizure drugs work
- Basic therapeutic considerations
- Classification of antiseizure drugs
- First-generation drugs
- Newer-generation antiseizure drugs
- Management of generalized convulsive status epilepticus
- 22. Drugs for muscle spasm and spasticity
- Drugs for spasticity
- Drugs for localized muscle spasm
- Cyclobenzaprine
- UNIT VI. Drugs for Pain
- 23. Local anesthetics
- Basic pharmacology of local anesthetics
- Properties of individual local anesthetics
- Clinical use of local anesthetics
- 24. Opioid analgesics, opioid antagonists, and nonopioid centrally acting analgesics
- Opioid analgesics
- Basic pharmacology of the opioids
- Opioid antagonists
- Nonopioid centrally acting analgesic—tramadol
- Prescribing opioids for chronic, noncancer pain during a national opioid crisis
- 25. Drugs for headache
- Migraine headache
- Cluster headaches
- Medication overuse headache
- UNIT VII. Psychotherapeutic Drugs
- 26. Antipsychotic agents and their use in schizophrenia
- Schizophrenia: Clinical presentation and etiology
- First-generation (conventional) antipsychotics
- Second-generation (atypical) antipsychotics
- Long-acting (depot) antipsychotic preparations
- Management of schizophrenia
- 27. Antidepressants
- Major depression: Clinical features, pathogenesis, and treatment overview
- Drugs used for depression
- Peripartum depression
- 28. Drugs for bipolar disorder
- Characteristics of bipolar disorder
- Treatment of bipolar disorder
- Mood-stabilizing drugs
- Antipsychotic drugs
- 29. Sedative-hypnotic drugs
- Benzodiazepines
- Benzodiazepine-like drugs
- Ramelteon: A melatonin agonist
- Suvorexant: An orexin antagonist
- Barbiturates
- Management of insomnia
- Other hypnotics
- 30. Management of anxiety disorders
- Generalized anxiety disorder
- Panic disorder
- Obsessive-compulsive disorder
- Social anxiety disorder
- Posttraumatic stress disorder
- 31. Central nervous system stimulants and attention-deficit/hyperactivity disorder
- Central nervous system stimulants
- Attention-deficit/hyperactivity disorder
- UNIT VIII. Substance Use Disorders
- 32. Substance use disorders I: Basic considerations
- Definitions
- Diagnostic criteria for substance use disorder
- Factors that contribute to substance use disorder
- Neurobiology of substance use disorders
- Principles of substance use disorder treatment
- Controlled substances act
- 33. Substance use disorders II: Alcohol
- Basic pharmacology of alcohol
- Alcohol use disorder
- Drugs for alcohol use disorder
- 34. Substance use disorders III: Nicotine and smoking
- Basic pharmacology of nicotine
- Pharmacologic aids to smoking cessation
- 35. Substance use disorders IV: Major drugs of misuse other than alcohol and nicotine
- Heroin, oxycodone, and other opioids
- Kratom
- General central nervous system depressants
- Psychostimulants
- Marijuana and related preparations
- Psychedelics
- Dextromethorphan
- 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)
- Inhalants
- UNIT IX. Drugs That Affect the Heart, Blood Vessels, Blood, and Blood Volume
- 36. Review of hemodynamics
- Overview of the circulatory system
- Regulation of cardiac output
- Regulation of arterial pressure
- 37. Diuretics
- Review of renal anatomy and physiology
- Introduction to diuretics
- Loop diuretics
- Thiazides and related diuretics
- Potassium-sparing diuretics
- 38. Drugs acting on the renin-angiotensin-aldosterone system
- Physiology of the renin-angiotensin-aldosterone system
- Angiotensin-converting enzyme inhibitors
- Angiotensin II receptor blockers
- Aliskiren, a direct renin inhibitor
- Aldosterone antagonists
- 39. Calcium channel blockers
- Calcium channel blockers: Classification and sites of action
- Nondihydropyridines—verapamil and diltiazem: Agents that act on vascular smooth muscle and the heart
- Dihydropyridines: Agents that act mainly on vascular smooth muscle
- 40. Vasodilators
- Basic concepts in vasodilator pharmacology
- Pharmacology of individual vasodilators
- 41. Drugs for hypertension
- Basic considerations in hypertension
- Management of chronic hypertension
- Drugs for hypertensive disorders of pregnancy
- 42. Drugs for heart failure
- Pathophysiology of heart failure
- Overview of drugs used to treat heart failure
- Digoxin, a cardiac glycoside
- Management of heart failure
- 43. Antidysrhythmic drugs
- Introduction to cardiac electrophysiology, dysrhythmias, and antidysrhythmic drugs
- Pharmacology of the antidysrhythmic drugs
- 44. Prophylaxis of atherosclerotic cardiovascular disease: Drugs that help normalize cholesterol and triglyceride levels
- Cholesterol
- Plasma lipoproteins
- Role of low-density lipoprotein cholesterol in atherosclerosis
- 2018 American College of Cardiology/American Heart Association guideline on the management of blood cholesterol
- Drugs and other products used to improve plasma lipid levels
- Drug selection
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
- Adenosine triphosphate-citrase lyase inhibitors
- 45. Drugs for angina pectoris
- Angina pectoris: Pathophysiology and treatment strategy
- Organic nitrates
- β blockers
- Calcium channel blockers
- Ranolazine
- Treatment measures
- 46. Anticoagulant and antiplatelet drugs
- Coagulation: Physiology and pathophysiology
- Overview of drugs for thromboembolic disorders
- Anticoagulants
- Direct oral anticoagulants
- Antiplatelet drugs
- 47. Drugs for deficiency anemias
- Red blood cell development
- Iron deficiency
- Vitamin B12 deficiency
- Folic acid deficiency
- UNIT X. Drugs for Endocrine Disorders
- 48. Drugs for diabetes
- Diabetes: Basic considerations
- Insulin
- Other medications for treatment of diabetes
- 49. Drugs for thyroid disorders
- Thyroid physiology
- Thyroid function tests
- Thyroid pathophysiology
- Thyroid hormone preparations for hypothyroidism
- Drugs for hyperthyroidism
- UNIT XI. Reproductive Health
- 50. Estrogens and progestins: Basic pharmacology and noncontraceptive applications
- The menstrual cycle
- Role of pituitary hormones
- Estrogens
- Drugs with estrogen activity
- Selective estrogen receptor modulators
- Progesterone
- Menopausal hormone therapy
- 51. Birth control
- Effectiveness of birth control methods
- Selecting a birth control method
- Oral contraceptives
- Combination contraceptives with novel delivery systems
- Long-acting contraceptives
- Spermicides
- Emergency contraception
- Drugs for medical abortion
- 52. Androgens
- Testosterone
- Clinical pharmacology of the androgens
- Androgen (anabolic steroid) misuse
- 53. Drugs for benign prostatic hyperplasia
- Benign prostatic hyperplasia
- 54. Drugs for sexual dysfunction
- Male sexual dysfunction
- Erectile dysfunction
- Premature ejaculation
- Female sexual dysfunction
- 55. Transgender health
- Considerations for gender-affirmation treatment
- Initiating therapy during adolescence
- Gender-affirming hormone therapy for transgender adolescents
- Gender-affirming hormone therapy for adults
- Medications for transitioning
- Patient education
- UNIT XII. Antiinflammatory, Antiallergic, and Immunologic Drugs
- 56. Review of the immune system
- Introduction to the immune system
- Antibody-mediated (humoral) immunity
- Cell-mediated immunity
- 57. Childhood immunization
- General considerations
- Target diseases
- Specific vaccines and toxoids
- 58. Antihistamines
- Histamine
- 59. Cyclooxygenase inhibitors, nonsteroidal antiinflammatory drugs, and acetaminophen
- Mechanism of action
- Classification of cyclooxygenase inhibitors
- First-generation nonsteroidal antiinflammatory drugs
- Second-generation nonsteroidal antiinflammatory drugs (cyclooxygenase-2 inhibitors, coxibs)
- Acetaminophen
- American heart association statement on cyclooxygenase inhibitors in chronic pain
- 60. Glucocorticoids in nonendocrine disorders
- Review of glucocorticoid physiology
- Pharmacology of glucocorticoids
- UNIT XIII. Drugs for Bone and Joint Disorders
- 61. Drug therapy for rheumatoid arthritis
- Pathophysiology of rheumatoid arthritis
- Overview of therapy
- Nonsteroidal antiinflammatory drugs
- Glucocorticoids
- Conventional disease-modifying antirheumatic drugs
- Biologic disease-modifying antirheumatic drugs
- Targeted disease-modifying antirheumatic drug: Janus kinase inhibitors
- 62. Drug therapy for gout
- Pathophysiology of gout
- Pharmacologic management of gout
- Drugs for acute gouty arthritis
- Drugs for hyperuricemia (Urate-lowering therapy)
- 63. Drugs affecting calcium levels and bone mineralization
- Calcium physiology
- Calcium-related pathophysiology
- Drugs for disorders involving calcium and bone mineralization
- Osteoporosis
- UNIT XIV. Respiratory Tract Drugs
- 64. Drugs for asthma and chronic obstructive pulmonary disease
- Basic considerations
- Antiinflammatory drugs
- Bronchodilators
- Management of asthma
- Management of chronic obstructive pulmonary disease
- 65. Drugs for allergic rhinitis, cough, and colds
- Drugs for allergic rhinitis
- Drugs for cough
- Cold remedies: Combination preparations
- UNIT XV. Gastrointestinal Drugs
- 66. Drugs for peptic ulcer disease
- Pathogenesis of peptic ulcers
- Overview of treatment
- Antibacterial drugs
- Histamine-2 receptor antagonists
- Proton pump inhibitors
- Other antiulcer drugs
- 67. Laxatives
- General considerations
- Basic pharmacology of laxatives
- Laxative misuse
- 68. Other gastrointestinal drugs
- Antiemetics
- Drugs for motion sickness
- Antidiarrheal agents
- Drugs for irritable bowel syndrome
- Drugs for inflammatory bowel disease
- Prokinetic agents
- Pancreatic enzymes
- Anorectal preparations
- UNIT XVI. Nutrition and Complementary Therapies
- 69. Vitamins
- Basic considerations
- Fat-soluble vitamins
- Water-soluble vitamins
- 70. Drugs for obesity
- Assessment of weight-related health risk
- Pathophysiology
- Overview of obesity treatment
- Anti-obesity drugs
- A note regarding drugs for weight loss
- 71. Complementary and alternative therapy
- Regulation of dietary supplements
- Standardization of herbal products
- Private quality certification programs
- Adverse interactions with conventional drugs
- Some commonly used dietary supplements
- Harmful supplements to avoid
- UNIT XVII. Therapy for Infectious and Parasitic Diseases
- 72. Basic principles of antimicrobial therapy
- Selective toxicity
- Classification of antimicrobial drugs
- Acquired resistance to antimicrobial drugs
- Selection of antibiotics
- Host factors that modify drug choice, route of administration, or dosage
- Dosage and duration of treatment
- Therapy with antibiotic combinations
- Prophylactic use of antimicrobial drugs
- Misuses of antimicrobial drugs
- Monitoring antimicrobial therapy
- 73. Drugs that weaken the bacterial cell wall I: Penicillins
- Introduction to the penicillins
- Properties of individual penicillins
- Penicillin V
- 74. Drugs that weaken the bacterial cell wall II: Other drugs
- Cephalosporins
- Carbapenems
- Other inhibitors of cell wall synthesis
- 75. Bacteriostatic inhibitors of protein synthesis
- Tetracyclines
- Macrolides
- Other bacteriostatic inhibitors of protein synthesis
- 76. Aminoglycosides: Bactericidal inhibitors of protein synthesis
- Basic pharmacology of the aminoglycosides
- Properties of individual aminoglycosides
- 77. Sulfonamide antibiotics and trimethoprim
- Sulfonamides
- Trimethoprim
- Trimethoprim/sulfamethoxazole
- 78. Drug therapy for urinary tract infections
- Organisms that cause urinary tract infections
- Specific urinary tract infections and their treatment
- Urinary tract antiseptics
- 79. Drug therapy for tuberculosis
- Pathogenesis of tuberculosis
- Overview of treatment
- Treatment of latent tuberculosis
- Vaccination against tuberculosis
- Pharmacology of antituberculosis drugs
- Ethambutol
- Second-line antituberculosis drugs
- 80. Miscellaneous antibacterial drugs
- Fluoroquinolones
- Additional antibacterial drugs
- 81. Antifungal agents
- Fungal infections
- Systemic mycoses
- Antifungal drug classes
- Other azoles
- 82. Antiviral agents I: Drugs for non-HIV viral infections
- Drugs for infection with herpes simplex viruses and varicella zoster virus
- Drugs for cytomegalovirus infection
- Drugs for hepatitis C
- Drugs for hepatitis B
- Interferon alpha and hepatitis B
- Tenofovir
- Drugs for influenza
- COVID-19 prophylaxis
- 83. Antiviral agents II: Drugs for HIV infection
- Pathophysiology of human immunodeficiency virus infection
- Antiretroviral drugs
- Nucleoside/nucleotide reverse transcriptase inhibitors
- Nonnucleoside reverse transcriptase inhibitors
- Management of human immunodeficiency virus infection
- Human immunodeficiency virus infection prophylaxis
- Keeping current
- 84. Drug therapy for sexually transmitted infections
- Chlamydial infections
- Gonococcal infections
- Syphilis
- Bacterial vaginosis
- Trichomoniasis
- Genital herpes
- Nongonococcal urethritis
- Pelvic inflammatory disease
- Acute epididymitis
- Proctitis
- Anogenital warts
- Putting it all together
- 85. Anthelmintics
- Classification of parasitic worms
- Helminthic infestations
- Drugs of choice for helminthiasis
- UNIT XVIII. Cancer Therapy
- 86. Introduction to immunomodulators
- Monoclonal antibodies—“mAbs”
- Monoclonal antibodies for asthma
- Monoclonal antibodies for migraine prevention
- Common adverse reactions to monoclonal antibodies
- Tyrosine kinase inhibitors—“nibs”
- Proteasome inhibitors—“mibs”
- Immunotherapy in the future
- 87. Supportive care of patients receiving anticancer drugs
- The role of the nonspecialist
- What is cancer?
- Treatment of cancer
- Introduction to the cytotoxic anticancer drugs
- Cytotoxic agents
- Hormonal agents, targeted drugs, and other noncytotoxic anticancer drugs
- Interaction with CYP2D6 inhibitors
- Chemoprevention and cancer immunotherapy
- 88. Drugs for cancer pain
- Pain in cancer patients
- Management strategy
- Assessment and ongoing evaluation
- Drug therapy
- Nondrug therapy
- Patient education
- UNIT XIX. Drugs for Eyes, Ears, and Skin
- 89. Drugs for disorders of the eye
- Glaucoma
- Conjunctivitis
- Allergic conjunctivitis
- Additional ophthalmic drugs
- 90. Drugs for disorders of the skin
- Topical drug formulations
- Acne
- Drugs for psoriasis
- Drugs for atopic dermatitis (eczema)
- Agents for wart removal
- Drugs for ectoparasites
- Drugs for impetigo
- Drugs for management or prevention of miscellaneous skin conditions
- 91. Drugs for disorders of the ear
- Otitis media and its management
- Otitis media with effusion
- Acute otitis externa
- UNIT XX. Drug Therapy in Acute Care
- 92. Agents a ffecting the volume and ion content of body fluids
- Disorders of fluid volume and osmolality
- Acid-base disturbances
- Magnesium imbalances
- 93. Management of ST-Elevation myocardial infarction
- Pathophysiology of STEMI
- Management of ST-segment elevation myocardial infarction
- Complications of STEMI
- Secondary prevention of STEMI
- 94. Drugs for acute care
- Anesthesia, neuromuscular blockers, and analgesia
- Cardiology
- Hematology
- Nephrology
- Appendix: Canadian drug information
- Index
- Edition: 3
- Published: October 16, 2024
- Imprint: Elsevier
- Language: English
- Paperback ISBN: 9780323936064
- eBook ISBN: 9780323936798
LR
Laura D. Rosenthal
Assistant Dean for DNP Programs, College of Nursing, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
Affiliations and expertise
Professor, College of Nursing, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USAJB
Jacqueline Rosenjack Burchum
Associate Professor Jacqueline Rosenjack Burchum works at the College of Nursing, Department of Advanced Practice and Doctoral Studies, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Affiliations and expertise
Associate Professor, College of Nursing, Department of Advanced Practice and Doctoral Studies, University of Tennessee Health Science Center, Memphis, Tennessee, USA